Michel Fay
Overview
Explore the profile of Michel Fay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dezitter X, Fagart J, Taront S, Fay M, Masselot B, Hetuin D, et al.
Mol Pharmacol
. 2013 Nov;
85(2):226-36.
PMID: 24225022
There is a therapeutic need for glucocorticoid receptor (GR) ligands that distinguish between the transrepression and transactivation activity of the GR, the later thought to be responsible for side effects....
2.
Khan J, Tikad A, Fay M, Hamze A, Fagart J, Chabbert-Buffet N, et al.
Mol Endocrinol
. 2013 Apr;
27(6):909-24.
PMID: 23579486
Currently available progesterone (P4) receptor (PR) antagonists, such as mifepristone (RU486), lack specificity and display partial agonist properties, leading to potential drawbacks in their clinical use. Recent x-ray crystallographic studies...
3.
Hubert E, Teissier R, Fernandes-Rosa F, Fay M, Rafestin-Oblin M, Jeunemaitre X, et al.
J Am Soc Nephrol
. 2011 Sep;
22(11):1997-2003.
PMID: 21903996
Pseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease of mineralocorticoid resistance characterized by salt wasting and failure to thrive in infancy. Here we describe the first case of a...
4.
Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, et al.
J Biol Chem
. 2010 Jul;
285(39):29932-40.
PMID: 20650892
Limitations of current steroidal mineralocorticoid receptor (MR) antagonists have stimulated the search for a new generation of molecules. We screened for novel nonsteroidal compounds and identified MR antagonists derived from...
5.
Petit-Topin I, Turque N, Fagart J, Fay M, Ulmann A, Gainer E, et al.
Mol Pharmacol
. 2009 Mar;
75(6):1317-24.
PMID: 19289570
Many progestins have been developed for use in contraception, menopausal hormone therapy, and treatment of gynecological diseases. They are derived from either progesterone or testosterone, and they act by binding...
6.
Le Moellic C, Boulkroun S, Gonzalez-Nunez D, Dublineau I, Cluzeaud F, Fay M, et al.
Am J Physiol Cell Physiol
. 2005 Aug;
289(6):C1513-21.
PMID: 16107502
Aldosterone classically modulates Na transport in tight epithelia such as the renal collecting duct (CD) through the transcellular route, but it is not known whether the hormone could also affect...
7.
Le Moellic C, Ouvrard-Pascaud A, Capurro C, Cluzeaud F, Fay M, Jaisser F, et al.
J Am Soc Nephrol
. 2004 Apr;
15(5):1145-60.
PMID: 15100355
Effects of aldosterone on its target cells have long been considered to be mediated exclusively through the genomic pathway; however, evidence has been provided for rapid effects of the hormone...
8.
Malbert-Colas L, Fay M, Cluzeaud F, Blot-Chabaud M, Farman N, Dhermy D, et al.
Pflugers Arch
. 2003 Aug;
447(1):35-43.
PMID: 12908109
Ubiquitination of proteins such as ion transporters appears to be an important process in the regulation of their membrane expression. Recently, using two-hybrid screening, we have selected a potential partner...
9.
Farman N, Fay M, Cluzeaud F
Ann N Y Acad Sci
. 2003 May;
986:428-36.
PMID: 12763861
The gamma subunit of Na/K/ATPase is a small membrane protein that shares homologies with other members of the FXYD family, like phospholemman and CHIF (corticosteroid hormone-induced factor). Both the gamma...
10.
Bocchi B, Fagart J, Cluzeaud F, Fay M, Rafestin-Oblin M, Farman N
J Steroid Biochem Mol Biol
. 2003 Apr;
84(2-3):239-44.
PMID: 12711009
The mineralocorticoid receptor (MR) binds aldosterone, but also glucocorticoid hormones (corticosterone in rodents, cortisol in humans), which largely prevail in the plasma. To prevent permanent and maximal occupancy of MR...